422 results
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
, is available on our website: https://www.sanofi.com/en/science-and-innovation/research-and-development
Consumer Healthcare
Net sales (€ million)
Q4
6-K
EX-99.1
SNY
Sanofi
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
continues to drive innovation and deliver for patients. Under Paul’s leadership and his Play to Win strategy, Sanofi has set out on a course built
6-K
EX-99.5
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
disease that progresses more rapidly than T.b. gambiense, killing quickly if untreated. Until now, due to the lack of innovation for this strain
6-K
EX-99.2
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
our commitment to advancing scientific innovation for people living with multiple myeloma, and we look forward to sharing more detail on Sarclisa’s
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
to fund innovation and growth drivers
Announces intention to separate the Consumer Healthcare Business at the earliest in Q4 2024 via the creation … ).
An update of the R&D pipeline as of September 30, 2023, is available on our website: https://www.sanofi.com/en/science-and-innovation/research
6-K
EX-99.1
l8fl6z68u hld1h
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
EX-99.2
fznzxwu6bwkpl3wq53
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
lhqet76
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
6-K
EX-99.1
xn3 vivxndydsj
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
zcjuq7h ep
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.3
qv8k2yo50 wmi
5 Jul 23
Current report (foreign)
8:43am
6-K
EX-99.1
xuvq1515
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.2
sl0i9fqqinl
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.3
i1u1l0
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
pghwvvjj
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
cwo2hpbb66gm c0r
2 Dec 22
Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease
10:40am
6-K
EX-99.1
qypihitt534qc9 dn
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.2
kl1ngg2w0ydam3pp 3p
2 Sep 22
Current report (foreign)
9:44am
6-K
EX-99.1
ocrxn5mom6
2 Sep 22
Current report (foreign)
9:44am
6-K
EX-99.1
5wp r7gxafuux
8 Aug 22
Sanofi and Innovent Biologics enter strategic
4:27pm